{
  "case_info": {
    "docket_number": "C-4456",
    "company": {
      "name": "GeneLink, Inc.",
      "incorporation_state": "Pennsylvania",
      "entity_type": "corporation",
      "address": "8250 Exchange Drive, Suite 120, Orlando, Florida 32809",
      "business_description": "GeneLink, Inc., also doing business as GeneLink Biosciences, Inc., develops, advertises, labels, offers for sale, and sells nutritional supplements and skincare products through a multi-level marketing system utilizing affiliates and licensees. The company customizes nutritional supplements and skincare products to each consumer's genetic profile using DNA assessment based on genetic variations (SNPs)."
    },
    "commissioners": [
      "Edith Ramirez, Chairwoman",
      "Julie Brill",
      "Maureen K. Ohlhausen",
      "Joshua D. Wright",
      "Terrell McSweeny"
    ],
    "case_date": {
      "month": 5,
      "year": 2014
    },
    "legal_authority": "Federal Trade Commission Act, 15 U.S.C. § 45 et seq.",
    "violation_type": "deceptive",
    "ftc_url": "https://www.ftc.gov/legal-library/browse/cases-proceedings/112-3095-genelink-inc-matter"
  },
  "complaint": {
    "factual_background": "GeneLink and foruTM International Corporation marketed genetically customized nutritional supplements and skincare products based on DNA assessments. The companies collected genetic information from nearly 30,000 consumers since 2008, claiming their products were scientifically proven to compensate for genetic disadvantages. They also made false representations about their data security practices while failing to implement reasonable safeguards for consumers' sensitive personal information, including Social Security numbers and genetic data.",
    "representations_made": [
      {
        "description": "Claimed that genetic disadvantages identified through DNA Assessments are scientifically proven to be mitigated or compensated for with nutritional supplementation",
        "quoted_text": "12. Through the means described in Paragraph 11, respondents have represented, expressly or by implication, that genetic disadvantages identified through respondents’ DNA Assessments are scientifically proven to be mitigated or compensated for with nutritional supplementation.",
        "verified": true,
        "confidence": 1.0,
        "source_paragraph": 12,
        "quote_start_line": 347,
        "quote_end_line": 349
      },
      {
        "description": "Claimed that custom-blended nutritional supplements effectively compensate for genetic disadvantages identified by DNA Assessments, thereby reducing an individual's risk of impaired health or illness",
        "quoted_text": "14. Through the means described in Paragraph 11, respondents have represented, expressly or by implication, that their custom-blended nutritional supplements effectively compensate for genetic disadvantages identified by respondents’ DNA Assessments, thereby reducing an individual’s risk of impaired health or illness.",
        "verified": true,
        "confidence": 1.0,
        "source_paragraph": 14,
        "quote_start_line": 354,
        "quote_end_line": 357
      },
      {
        "description": "Claimed through testimonials that custom-blended nutritional supplements treat or mitigate diabetes, heart disease, arthritis, and insomnia",
        "quoted_text": "17. Through the use of testimonials, as described in Paragraph 11, respondents have represented, expressly or by implication, that their custom-blended nutritional supplements treat or mitigate diabetes, heart disease, arthritis, and insomnia, among other ailments.",
        "verified": true,
        "confidence": 1.0,
        "source_paragraph": 17,
        "quote_start_line": 367,
        "quote_end_line": 369
      },
      {
        "description": "Claimed that genetically customized skin repair serum is scientifically proven to reduce the appearance of wrinkles and improve skin firmness, and enhance or diminish aging predispositions including collagen breakdown, sun damage, and oxidative stress",
        "quoted_text": "20. Through the means described in Paragraph 11, including, but not necessarily limited to, the statements and depictions contained in the materials attached as Exhibit I, respondents have represented, expressly or by implication, that their genetically customized skin repair serum is scientifically proven to: (a) reduce the appearance of wrinkles and improve skin firmness; and (b) enhance or diminish aging predispositions, including collagen breakdown, sun damage, and oxidative stress.",
        "verified": true,
        "confidence": 1.0,
        "source_paragraph": 20,
        "quote_start_line": 376,
        "quote_end_line": 381
      },
      {
        "description": "Claimed that they implement reasonable and appropriate measures to secure consumers' personal information",
        "quoted_text": "31. Through the means described in Paragraph 28, respondents have represented, expressly or by implication, that they implement reasonable and appropriate measures to secure consumers’ personal information.",
        "verified": true,
        "confidence": 1.0,
        "source_paragraph": 31,
        "quote_start_line": 465,
        "quote_end_line": 467
      }
    ],
    "counts": [
      {
        "count_number": 1,
        "title": "False Claims About Scientific Proof for Genetic Disadvantage Mitigation",
        "representation": "Genetic disadvantages identified through respondents' DNA Assessments are scientifically proven to be mitigated or compensated for with nutritional supplementation",
        "fact": "Genetic disadvantages identified through respondents' DNA Assessments are not scientifically proven to be mitigated or compensated for with nutritional supplementation",
        "conclusion": "Therefore, the representation set forth in Paragraph 12 was, and is, false or misleading."
      },
      {
        "count_number": 2,
        "title": "Lack of Substantiation for Custom Supplement Efficacy Claims",
        "representation": "Their custom-blended nutritional supplements effectively compensate for genetic disadvantages identified by respondents' DNA Assessments, thereby reducing an individual's risk of impaired health or illness",
        "fact": "Respondents did not possess and rely upon a reasonable basis that substantiated the representation set forth in Paragraph 14, at the time the representation was made",
        "conclusion": "Therefore, the representation set forth in Paragraph 15 was, and is, false or misleading."
      },
      {
        "count_number": 3,
        "title": "Lack of Substantiation for Disease Treatment Claims",
        "representation": "Their custom-blended nutritional supplements treat or mitigate diabetes, heart disease, arthritis, and insomnia, among other ailments",
        "fact": "Respondents did not possess and rely upon a reasonable basis that substantiated the representations set forth in Paragraph 17, at the time the representations were made",
        "conclusion": "Therefore, the representation set forth in Paragraph 18 was, and is, false or misleading."
      },
      {
        "count_number": 4,
        "title": "False Claims About Skin Repair Serum Efficacy",
        "representation": "Their genetically customized skin repair serum is scientifically proven to: (a) reduce the appearance of wrinkles and improve skin firmness; and (b) enhance or diminish aging predispositions, including collagen breakdown, sun damage, and oxidative stress",
        "fact": "Respondents' genetically customized skin repair serum is not scientifically proven to: (a) reduce the appearance of wrinkles and improve skin firmness; or (b) enhance or diminish aging predispositions, including collagen breakdown, sun damage, and oxidative stress",
        "conclusion": "Therefore, the representations set forth in Paragraph 20 were, and are, false or misleading."
      },
      {
        "count_number": 5,
        "title": "False Data Security Representations",
        "representation": "They implement reasonable and appropriate measures to secure consumers' personal information",
        "fact": "Respondents have not implemented reasonable and appropriate measures to protect consumers' personal information from unauthorized access",
        "conclusion": "Therefore, the representation set forth in Paragraph 31 was, and is, false or misleading."
      },
      {
        "count_number": 6,
        "title": "Unfair Data Security Practices",
        "representation": "Respondents failed to employ reasonable and appropriate measures to prevent unauthorized access to consumers' personal information",
        "fact": "Respondents failed to implement reasonable policies and procedures, failed to require appropriate safeguards from service providers, failed to provide reasonable oversight of service providers, created unnecessary risks by maintaining information in clear text and providing unrestricted access, and did not use readily available security measures to limit wireless access",
        "conclusion": "Respondents' practices are likely to cause substantial injury to consumers that is not reasonably avoidable by consumers themselves and is not outweighed by countervailing benefits to consumers or competition. This practice was, and is, an unfair act or practice."
      }
    ]
  },
  "order": {
    "definitions": {
      "respondent": "GeneLink, Inc., a corporation, also doing business as GeneLink Biosciences, Inc., its successors and assigns, and its officers, agents, representatives, and employees.",
      "Commerce": "as defined in Section 4 of the Federal Trade Commission Act (\"FTC Act\"), 15 U.S.C. § 44.",
      "Covered Product": "any drug, food, or cosmetic that is: (a) customized or personalized for a consumer based on that consumer's DNA or SNP (single nucleotide polymorphism) assessment, including, but not limited to, LifeMap ME DNA Customized Nutritional Supplements, GeneWize Nutritional Supplements, LifeMap ME DNA Customized Skin Repair Serum, and GeneWize Customized Skin Repair Serum; or (b) promoted to modulate the effect of genes.",
      "Covered Assessment": "any genetic test or assessment, including, but not limited to, the Healthy Aging Assessment and LifeMap Healthy Aging Assessment.",
      "Essentially Equivalent Product": "a product that contains the identical ingredients, except for inactive ingredients (e.g., binders, colors, fillers, excipients), in the same form and dosage, and with the same route of administration (e.g., orally, sublingually), as the Covered Product; provided that the Covered Product may contain additional ingredients if reliable scientific evidence generally accepted by experts in the field demonstrates that the amount and combination of additional ingredients is unlikely to impede or inhibit the effectiveness of the ingredients in the Essentially Equivalent Product.",
      "Drug": "as defined in Section 15(c) of the FTC Act, 15 U.S.C. § 55(c).",
      "Food": "as defined in Section 15(b) of the FTC Act, 15 U.S.C. § 55(b).",
      "Cosmetic": "as defined in Section 15(e) of the FTC Act, 15 U.S.C. § 55(e).",
      "Adequate and well-controlled human clinical study": "a human clinical study that: is randomized and adequately controlled; utilizes valid end points generally recognized by experts in the relevant disease field; yields statistically significant between-group results; and is conducted by persons qualified by training and experience to conduct such a study. Such study shall be double-blind and placebo-controlled; provided, however, that, any study of a conventional food need not be placebo-controlled or double-blind if placebo control or blinding cannot be effectively implemented given the nature of the intervention. For the purposes of this proviso, \"conventional food\" does not include any dietary supplement, any customized or personalized product based on a consumer's DNA or SNP assessment, or any product promoted to modulate the effect of genes. Respondent shall have the burden of proving that placebo-control or blinding cannot be effectively implemented.",
      "Endorsement": "as defined in the Commission's Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 C.F.R. § 255.0.",
      "Licensee": "a person or entity, including a sublicensee, with whom respondent or its licensee has a business agreement.",
      "Affiliate": "any person or entity who participates in an Affiliate Program.",
      "Affiliate Program": "any arrangement whereby any person or entity: (a) provides respondent with, or refers to respondent, potential or actual customers; or (b) otherwise markets, advertises, or offers for sale any product or service on behalf of respondent.",
      "Personal Information": "individually identifiable information from or about an individual consumer, including, but not limited to: (a) a first and last name; (b) a home or other physical address, including street name and name of city or town; (c) an email address or other online contact information, such as an instant messaging user identifier or a screen name; (d) a telephone number; (e) a Social Security number; (f) a bank account, debit card, or credit card account number; (g) a persistent identifier, such as a customer number held in a \"cookie\" or processor serial number; or (h) clinical laboratory testing information, including test results. For the purpose of this provision, a \"consumer\" shall mean any person, including, but not limited to, any user of respondent's services, any employee of respondent, or any individual seeking to become an employee, where \"employee\" shall mean an agent, servant, salesperson, associate, independent contractor, or other person directly or indirectly under the control of respondent."
    },
    "provisions": [
      {
        "provision_number": "I",
        "title": "Prohibition on Disease Treatment Claims Without Substantiation",
        "category": "prohibition",
        "summary": "Respondent must not make representations that Covered Products are effective in treating or preventing disease unless substantiated by at least two adequate and well-controlled human clinical studies.",
        "requirements": [
          {
            "description": "Must not represent that Covered Product is effective in treating or preventing disease without at least two adequate and well-controlled human clinical studies",
            "quoted_text": "IT IS ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, licensee, affiliate, trade name, or other device, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product, in or affecting commerce, shall not make any representation, in any manner, expressly or by implication, including through the use of a product name, endorsement, depiction, illustration, trademark, or trade name, that such product is effective in the diagnosis, cure, mitigation, treatment, or prevention of any disease, including, but not limited to, any 3 representation that the product will treat, prevent, mitigate, or reduce the risk of diabetes, heart disease, arthritis, or insomnia, unless the representation is non-misleading and, at the time the representation is made, respondent possesses and relies upon competent and reliable scientific evidence that substantiates that the representation is true. For purposes of this Part I, “competent and reliable scientific evidence” shall consist of at least two adequate and well-controlled human clinical studies of the Covered Product, or of an Essentially Equivalent Product, conducted by different researchers, independently of each other, that conform to acceptable designs and protocols and whose results, when considered in light of the entire body of relevant and reliable scientific evidence, are sufficient to substantiate that the representation is true; provided that, if the respondent represents that such product is effective in the diagnosis, cure, mitigation, treatment, prevention, or the reduction of risk of disease for persons with a particular genetic variation or single nucleotide polymorphism (“SNP”), then studies required under this Part I shall be conducted on human subjects with such genetic variation or SNP. Respondent shall have the burden of proving that a product satisfies the definition of an Essentially Equivalent Product.",
            "deadline": null,
            "verified": true,
            "confidence": 0.85,
            "quote_start_line": 108,
            "quote_end_line": 132
          }
        ]
      },
      {
        "provision_number": "II",
        "title": "Prohibition on Health Benefit Claims Without Substantiation",
        "category": "prohibition",
        "summary": "Respondent must not make representations about health benefits, performance, or efficacy of Covered Products or Covered Assessments unless substantiated by competent and reliable scientific evidence.",
        "requirements": [
          {
            "description": "Must not make health benefit, performance, or efficacy representations about Covered Products or Covered Assessments without competent and reliable scientific evidence",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, licensee, affiliate, trade name, or other device, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product or any Covered Assessment, in or affecting commerce, shall not make any representation, in any manner, expressly or by implication, including through the use of a product name, endorsement, depiction, or illustration, other than representations covered under Part I of this order, about the health benefits, performance, or efficacy of any Covered Product or any Covered Assessment, unless the representation is non-misleading, and, at the time of making such representation, respondent possesses and relies upon competent and reliable scientific evidence that is sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true. For purposes of this Part II, competent and reliable scientific evidence means tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons and are generally accepted in the profession to yield accurate and reliable results.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 134,
            "quote_end_line": 148
          }
        ]
      },
      {
        "provision_number": "III",
        "title": "Prohibition on Misrepresentations About Scientific Evidence",
        "category": "prohibition",
        "summary": "Respondent must not misrepresent the existence, contents, validity, results, or conclusions of any test, study, or research, or that benefits are scientifically proven.",
        "requirements": [
          {
            "description": "Must not misrepresent the existence, contents, validity, results, or conclusions of any test, study, or research",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, licensee, affiliate, trade name, or other device, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product or any Covered Assessment, in or affecting commerce, shall not misrepresent, in any manner, directly or indirectly, expressly or by implication, including through the use of endorsements: 4 A. The existence, contents, validity, results, or conclusions of any test, study, or research; or",
            "deadline": null,
            "verified": true,
            "confidence": 0.85,
            "quote_start_line": 150,
            "quote_end_line": 160
          },
          {
            "description": "Must not misrepresent that the benefits of any Covered Product or Covered Assessment are scientifically proven",
            "quoted_text": "B. That the benefits of any Covered Product or Covered Assessment are scientifically proven.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 161,
            "quote_end_line": 162
          }
        ]
      },
      {
        "provision_number": "IV",
        "title": "Safe Harbor for FDA-Approved Claims",
        "category": "acknowledgment",
        "summary": "Parts I-III do not prohibit representations specifically permitted by FDA regulations or approved drug applications.",
        "requirements": [
          {
            "description": "Permitted to make representations allowed by FDA Nutrition Labeling and Education Act regulations or Food and Drug Administration Modernization Act",
            "quoted_text": "A. Nothing in Parts I through III of this order shall prohibit respondent from making any representation for any product that is specifically permitted in labeling for such product by regulations promulgated by the Food and Drug Administration pursuant to the Nutrition Labeling and Education Act of 1990 or permitted under Sections 303-304 of the Food and Drug Administration Modernization Act of 1997; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 165,
            "quote_end_line": 170
          },
          {
            "description": "Permitted to make representations allowed in FDA-approved drug labeling",
            "quoted_text": "B. Nothing in Parts I through III of this order shall prohibit respondent from making any representation for any drug that is permitted in labeling for such drug under any tentative final or final standard promulgated by the Food and Drug Administration, or any new drug application approved by the Food and Drug Administration.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 171,
            "quote_end_line": 175
          }
        ]
      },
      {
        "provision_number": "V",
        "title": "Prohibition on Providing Means and Instrumentalities",
        "category": "prohibition",
        "summary": "Respondent must not provide licensees or affiliates with materials that would enable them to make prohibited representations.",
        "requirements": [
          {
            "description": "Must not provide means and instrumentalities to any person or entity to make representations prohibited by Parts I-III",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, licensee, affiliate, trade name, or other device, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product or any Covered Assessment, in or affecting commerce, shall not provide to any person or entity the means and instrumentalities with which to make, directly or by implication, any representations prohibited by Parts I through III of this order. For purposes of this Part, “means and instrumentalities” shall mean any information, document, or article referring or relating to any Covered Product or any Covered Assessment, including, but not limited to, any advertising, labeling, promotional, or purported substantiation materials, for use by licensees or affiliates in their marketing of any Covered Product or any Covered Assessment in or affecting commerce.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 177,
            "quote_end_line": 187
          }
        ]
      },
      {
        "provision_number": "VI",
        "title": "Affiliate Monitoring and Compliance Program",
        "category": "affirmative_obligation",
        "summary": "Respondent must establish and maintain a system to monitor affiliates' representations, including monthly reviews of top 50 affiliates and random samples, and terminate non-compliant affiliates within 7 days.",
        "requirements": [
          {
            "description": "Establish and maintain a system to monitor and review affiliates' representations for compliance with Parts I-III",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, trade name, or other device, in connection with the manufacturing, advertising, labeling, promotion, offering for sale, sale, or distribution of any product or service, in or affecting commerce, shall take steps sufficient to ensure compliance with Parts I through III of this order. Such steps shall include, at a minimum: 5 A. Establishing, implementing, and thereafter maintaining a system to monitor and review its affiliates’ representations and disclosures to ensure compliance with Parts I through III of this order. The system shall be implemented as follows:",
            "deadline": "30 days",
            "verified": true,
            "confidence": 0.85,
            "quote_start_line": 189,
            "quote_end_line": 199
          },
          {
            "description": "Determine top 50 revenue-generating affiliates on semi-annual basis",
            "quoted_text": "1. No later than thirty (30) days after the date of service of this order, and, on a semi-annual basis thereafter, respondent shall determine those affiliates that generate the most sales for respondent. For respondent’s top fifty (50) revenue-generating affiliates, respondent shall:",
            "deadline": "30 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 200,
            "quote_end_line": 203
          },
          {
            "description": "Monitor and review top 50 affiliates' websites monthly at undisclosed times",
            "quoted_text": "(a) Monitor and review each affiliate’s web sites on at least a monthly basis at times not disclosed in advance to its affiliates and in a manner reasonably calculated not to disclose the source of the monitoring activity at the time it is being conducted; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 204,
            "quote_end_line": 207
          },
          {
            "description": "Conduct monthly online monitoring of top 50 affiliates on social networks, Twitter, YouTube",
            "quoted_text": "(b) Conduct online monitoring and review of the Internet on at least a monthly basis, including, but not limited to, social networks such as Facebook, microsites such as Twitter, and video sites such as YouTube, for any representations by such affiliates.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 208,
            "quote_end_line": 211
          },
          {
            "description": "Select random sample of 50 affiliates from remainder on semi-annual basis",
            "quoted_text": "2. For the remainder of respondent’s affiliates, no later than thirty (30) days after the date of service of this order, and, on a semi-annual basis thereafter, respondent shall select a random sample of fifty (50) affiliates. Respondent shall:",
            "deadline": "30 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 212,
            "quote_end_line": 215
          },
          {
            "description": "Monitor and review randomly selected affiliates' websites monthly at undisclosed times",
            "quoted_text": "(a) Monitor and review each of these randomly selected affiliates’ web sites on at least a monthly basis at times not disclosed in advance to its affiliates and in a manner reasonably calculated not to disclose the source of the monitoring activity at the time it is being conducted; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 216,
            "quote_end_line": 220
          },
          {
            "description": "Conduct monthly online monitoring of randomly selected affiliates on social networks, Twitter, YouTube",
            "quoted_text": "(b) Conduct online monitoring and review of the Internet on at least a monthly basis, including, but not limited to, social networks such as Facebook, microsites such as Twitter, and video sites such as YouTube, for any representations by such affiliates.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 221,
            "quote_end_line": 224
          },
          {
            "description": "Terminate non-compliant affiliates and cease payment within 7 days of reasonably concluding violations occurred",
            "quoted_text": "B. Within seven (7) days of reasonably concluding that an affiliate has made representations that the affiliate knew or should have known violated Parts I, II, or III of this order, respondent shall terminate the affiliate from any affiliate program and cease payment to the affiliate; provided, however, that nothing in this subpart shall prevent respondent from honoring respondent’s payment obligation to an affiliate pursuant to a contract executed by the affiliate and respondent prior to the date of service of the order; and",
            "deadline": "7 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 225,
            "quote_end_line": 231
          },
          {
            "description": "Create and maintain compliance reports and make available within 14 days of FTC request",
            "quoted_text": "C. Creating, and thereafter, maintaining, and within fourteen (14) days of receipt of a written request from a representative of the Federal Trade Commission, making available for inspection and copying, reports sufficient to show compliance with this Part of the order.",
            "deadline": "14 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 232,
            "quote_end_line": 235
          }
        ]
      },
      {
        "provision_number": "VII",
        "title": "Prohibition on Privacy and Security Misrepresentations",
        "category": "prohibition",
        "summary": "Respondent must not misrepresent the extent to which it maintains and protects the privacy, confidentiality, security, or integrity of Personal Information.",
        "requirements": [
          {
            "description": "Must not misrepresent the extent to which it maintains and protects privacy, confidentiality, security, or integrity of Personal Information",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, licensee, affiliate, trade name, or other device, in connection with the manufacturing, advertising, labeling, promotion, offering for sale, sale, or distribution of any product or service, in or affecting commerce, shall not misrepresent in any manner, expressly or by implication, the extent to which it maintains and protects the privacy, confidentiality, security, or integrity of Personal Information collected from or about consumers.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 240,
            "quote_end_line": 245
          }
        ]
      },
      {
        "provision_number": "VIII",
        "title": "Information Security Program",
        "category": "affirmative_obligation",
        "summary": "Respondent must establish and maintain a comprehensive written information security program with administrative, technical, and physical safeguards to protect Personal Information.",
        "requirements": [
          {
            "description": "Establish and implement comprehensive information security program to protect Personal Information",
            "quoted_text": "IT IS FURTHER ORDERED that respondent, directly or through any corporation, partnership, subsidiary, division, trade name, or other device, shall, no later than the date of service of this order, establish and implement, and thereafter maintain, a comprehensive information security program that is reasonably designed to protect the security, confidentiality, and integrity of Personal Information collected from or about consumers. Such program, the content and implementation of which must be fully documented in writing, shall contain administrative, technical, and physical safeguards appropriate to respondent’s size and complexity, the nature and scope of respondent’s activities, and the sensitivity of the Personal Information respondent collects from or about consumers, including:",
            "deadline": "date of service",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 247,
            "quote_end_line": 255
          },
          {
            "description": "Designate employee(s) to coordinate and be accountable for the information security program",
            "quoted_text": "A. The designation of an employee or employees to coordinate and be accountable for the information security program;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 256,
            "quote_end_line": 257
          },
          {
            "description": "Identify and assess material internal and external risks to Personal Information security",
            "quoted_text": "B. The identification of material internal and external risks to the security, confidentiality, and integrity of Personal Information that could result in the unauthorized disclosure, misuse, loss, alteration, destruction, or other compromise of such information, and assessment of the sufficiency of any safeguards in place to control these risks. At a minimum, this risk assessment should include consideration of risks in each area of relevant operation, including, but not limited to: (1) employee training and management; (2) information systems, including network and software design, information processing, storage, transmission, and disposal; and (3) prevention, detection, and response to attacks, intrusions, or other systems failures;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 258,
            "quote_end_line": 267
          },
          {
            "description": "Design and implement reasonable safeguards and regularly test or monitor their effectiveness",
            "quoted_text": "C. The design and implementation of reasonable safeguards to control the risks identified through risk assessment, and regular testing or monitoring of the effectiveness of the safeguards’ key controls, systems, and procedures;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 268,
            "quote_end_line": 271
          },
          {
            "description": "Select and retain service providers capable of safeguarding Personal Information and require appropriate contractual safeguards",
            "quoted_text": "D. The development and use of reasonable steps to select and retain service providers capable of appropriately safeguarding Personal Information received from respondent, and requiring service providers by contract to implement and maintain appropriate safeguards; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 272,
            "quote_end_line": 275
          },
          {
            "description": "Evaluate and adjust information security program based on testing, monitoring, and material changes",
            "quoted_text": "E. The evaluation and adjustment of respondent’s information security program in light of the results of the testing and monitoring required by subpart C, any material changes to respondent’s operations or business arrangements, or any other circumstances that respondent knows or has reason to know may have a material impact on the effectiveness of its information security program.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 279,
            "quote_end_line": 283
          }
        ]
      },
      {
        "provision_number": "IX",
        "title": "Third-Party Security Assessments",
        "category": "assessment",
        "summary": "Respondent must obtain initial and biennial third-party security assessments for 20 years from qualified professionals (CISSP, CISA, or GIAC) and submit initial assessment to FTC within 10 days of completion.",
        "requirements": [
          {
            "description": "Obtain initial assessment covering first 180 days after service of order from qualified third-party professional",
            "quoted_text": "IT IS FURTHER ORDERED that, in connection with its compliance with Part VIII of this order, respondent shall obtain initial and biennial assessments and reports (“Assessments”) from a qualified, objective, independent third-party professional who uses procedures and standards generally accepted in the profession. Professionals qualified to prepare such assessments shall be: a person qualified as a Certified Information System Security Professional (CISSP) or as a Certified Information Systems Auditor (CISA); a person holding Global Information Assurance Certification (GIAC) from the SysAdmin, Audit, Network, Security (SANS) Institute; or a qualified person or organization approved by the Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, Washington, D.C. 20580. The reporting period for the Assessments shall cover: (1) the first one hundred and eighty (180) days after service of the order for the initial Assessment, and (2) each two (2) year period thereafter for twenty (20) years after service of the order for the biennial Assessments.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 285,
            "quote_end_line": 296
          },
          {
            "description": "Obtain biennial assessments for each 2-year period for 20 years after service of order",
            "quoted_text": "IT IS FURTHER ORDERED that, in connection with its compliance with Part VIII of this order, respondent shall obtain initial and biennial assessments and reports (“Assessments”) from a qualified, objective, independent third-party professional who uses procedures and standards generally accepted in the profession. Professionals qualified to prepare such assessments shall be: a person qualified as a Certified Information System Security Professional (CISSP) or as a Certified Information Systems Auditor (CISA); a person holding Global Information Assurance Certification (GIAC) from the SysAdmin, Audit, Network, Security (SANS) Institute; or a qualified person or organization approved by the Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, Washington, D.C. 20580. The reporting period for the Assessments shall cover: (1) the first one hundred and eighty (180) days after service of the order for the initial Assessment, and (2) each two (2) year period thereafter for twenty (20) years after service of the order for the biennial Assessments.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 285,
            "quote_end_line": 296
          },
          {
            "description": "Assessment must set forth specific safeguards implemented and maintained during reporting period",
            "quoted_text": "A. Set forth the specific administrative, technical, and physical safeguards that respondent has implemented and maintained during the reporting period;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 298,
            "quote_end_line": 299
          },
          {
            "description": "Assessment must explain appropriateness of safeguards to respondent's size, complexity, activities, and sensitivity of Personal Information",
            "quoted_text": "B. Explain how such safeguards are appropriate to respondent’s size and complexity, the nature and scope of its activities, and the sensitivity of the Personal Information collected from or about consumers;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 300,
            "quote_end_line": 302
          },
          {
            "description": "Assessment must explain how safeguards meet or exceed Part VIII requirements",
            "quoted_text": "C. Explain how the safeguards that have been implemented meet or exceed the protections required by Part VIII of this order; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 303,
            "quote_end_line": 304
          },
          {
            "description": "Assessment must certify that security program is operating effectively to protect Personal Information",
            "quoted_text": "D. Certify that respondent’s security program is operating with sufficient effectiveness to provide reasonable assurance that the security, confidentiality, and integrity of Personal Information is protected and has so operated throughout the reporting period.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 305,
            "quote_end_line": 308
          },
          {
            "description": "Complete each assessment within 60 days after end of reporting period",
            "quoted_text": "Each Assessment shall be prepared and completed within sixty (60) days after the end of the reporting period to which the Assessment applies. The respondent shall provide its initial",
            "deadline": "60 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 309,
            "quote_end_line": 310
          },
          {
            "description": "Provide initial assessment to FTC within 10 days after completion",
            "quoted_text": "reporting period to which the Assessment applies. The respondent shall provide its initial Assessment to the Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, Washington, D.C. 20580, within ten (10) days after the Assessment has been",
            "deadline": "10 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 310,
            "quote_end_line": 312
          },
          {
            "description": "Retain subsequent biennial assessments until order terminates and provide to FTC within 10 days of request",
            "quoted_text": "completed. All subsequent biennial Assessments shall be retained by respondent until the order is terminated and provided to the Associate Director for Enforcement within ten (10) days of request. Unless otherwise directed by a representative of the Commission in writing, the initial Assessment, and any subsequent Assessments requested, shall be sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, D.C. 8 20580. The subject line must begin: In the Matter of GeneLink, Inc., FTC File No. 112 3095. Provided, however, that in lieu of overnight courier, notices may be sent by first-class mail, but only if an electronic version of any such notice is contemporaneously sent to the Commission at Debrief@ftc.gov.",
            "deadline": "10 days",
            "verified": true,
            "confidence": 0.85,
            "quote_start_line": 313,
            "quote_end_line": 325
          }
        ]
      },
      {
        "provision_number": "X",
        "title": "Order Acknowledgment and Delivery",
        "category": "acknowledgment",
        "summary": "Respondent must deliver a copy of the order to all principals, officers, directors, Scientific Advisory Board members, licensees, and managers, and secure signed acknowledgments.",
        "requirements": [
          {
            "description": "Deliver copy of order to all current principals, officers, directors, Scientific Advisory Board members, licensees, and managers and secure signed acknowledgments",
            "quoted_text": "IT IS FURTHER ORDERED that respondent GeneLink, Inc., and its successors and assigns, shall deliver a copy of this order to all current and future principals, officers, directors, Scientific Advisory Board members, and licensees, and to employees having managerial responsibilities with respect to the subject matter of this order, and shall secure from each such person a signed and dated statement acknowledging receipt of the order. Respondent GeneLink, Inc., and its successors and assigns, shall deliver this order to current personnel within thirty (30) days after the date of service of this order, and to future personnel within thirty (30) days after",
            "deadline": "30 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 327,
            "quote_end_line": 333
          },
          {
            "description": "Deliver copy of order to future principals, officers, directors, Scientific Advisory Board members, licensees, and managers within 30 days of assuming position",
            "quoted_text": "IT IS FURTHER ORDERED that respondent GeneLink, Inc., and its successors and assigns, shall deliver a copy of this order to all current and future principals, officers, directors, Scientific Advisory Board members, and licensees, and to employees having managerial responsibilities with respect to the subject matter of this order, and shall secure from each such person a signed and dated statement acknowledging receipt of the order. Respondent GeneLink, Inc., and its successors and assigns, shall deliver this order to current personnel within thirty (30) days after the date of service of this order, and to future personnel within thirty (30) days after the person assumes such position or responsibilities.",
            "deadline": "30 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 327,
            "quote_end_line": 334
          }
        ]
      },
      {
        "provision_number": "XI",
        "title": "Recordkeeping Requirements",
        "category": "recordkeeping",
        "summary": "Respondent must maintain and make available for FTC inspection assessment materials for 3 years and advertising materials and substantiation for 5 years after last dissemination.",
        "requirements": [
          {
            "description": "Maintain all materials relied upon to prepare each assessment for 3 years after preparation date",
            "quoted_text": "IT IS FURTHER ORDERED that respondent GeneLink, Inc., and its successors and assigns, shall maintain and, upon request, make available to a representative to the Commission for inspection and copying: A. For a period of three (3) years after the date of preparation of each Assessment required under Part IX of this order, all materials relied upon to prepare the Assessment, whether prepared by or on behalf of respondent, including, but not limited to, all plans, reports, studies, reviews, audits, audit trails, policies, training materials, and assessments, and any other materials relating to respondent’s compliance with Parts VIII and IX of this order, for the compliance period covered by such Assessment;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 336,
            "quote_end_line": 345
          },
          {
            "description": "Maintain all advertisements and promotional materials containing representations for 5 years after last dissemination",
            "quoted_text": "B. Unless covered by Part XI.A, for a period of five (5) years after the last date of dissemination of any representation covered by this order, maintain and upon reasonable notice make available to the Commission for inspection and copying: 1. All advertisements and promotional materials containing the representation, including, but not limited to, all marketing and training materials distributed to licensees and affiliates;",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 346,
            "quote_end_line": 351
          },
          {
            "description": "Maintain all materials relied upon in disseminating representations for 5 years after last dissemination",
            "quoted_text": "2. All materials that were relied upon in disseminating the representation; and",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 352,
            "quote_end_line": 353
          },
          {
            "description": "Maintain all tests, reports, studies, and evidence that contradict representations or complaints for 5 years after last dissemination",
            "quoted_text": "3. All tests, reports, studies, surveys, demonstrations, or other evidence in that respondent’s possession or control that contradict, qualify, or call into question the representation, or the basis relied upon for the representation, including complaints and other communications with consumers or with governmental or consumer protection organizations.",
            "deadline": null,
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 354,
            "quote_end_line": 358
          }
        ]
      },
      {
        "provision_number": "XII",
        "title": "Notification of Corporate Changes",
        "category": "compliance_reporting",
        "summary": "Respondent must notify the FTC at least 30 days prior to any corporate change that may affect compliance obligations, including dissolution, merger, bankruptcy, or name/address changes.",
        "requirements": [
          {
            "description": "Notify FTC at least 30 days prior to any corporate change affecting compliance obligations (dissolution, merger, sale, bankruptcy, name/address change)",
            "quoted_text": "IT IS FURTHER ORDERED that respondent GeneLink, Inc., and its successors and assigns, shall notify the Commission at least thirty (30) days prior to any change in the corporation that may affect compliance obligations arising under this order, including, but not limited to, dissolution, assignment, sale, merger, or other action that would result in the emergence of a successor corporation; the creation or dissolution of a subsidiary, parent, or affiliate that engages in any acts or practices subject to this order; the proposed filing of a bankruptcy petition; or a change in the corporate name or address. Provided, however, that, with respect to any proposed change in the corporation about which respondent GeneLink, Inc., and its successors and assigns, learns less than thirty (30) days prior to the date such action is to take place, respondent GeneLink, Inc., and its successors and assigns, shall notify the Commission as soon as is practicable after obtaining such knowledge. Unless otherwise directed by a representative of the Commission in writing, all notices required by this Part shall be emailed to Debrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, D.C. 20580. The subject line must begin: In the Matter of GeneLink, Inc., FTC File No. 112 3095.",
            "deadline": "30 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 363,
            "quote_end_line": 378
          }
        ]
      },
      {
        "provision_number": "XIII",
        "title": "Compliance Reporting",
        "category": "compliance_reporting",
        "summary": "Respondent must file an initial compliance report within 60 days and submit additional reports within 10 days upon FTC request.",
        "requirements": [
          {
            "description": "File initial compliance report with FTC setting forth manner and form of compliance with order",
            "quoted_text": "IT IS FURTHER ORDERED that respondent GeneLink, Inc., and its successors and assigns, within sixty (60) days after service of this order, shall file with the Commission a true and accurate report, in writing, setting forth in detail the manner and form of its own compliance with this order. Within ten (10) days of receipt of written notice from a representative of the",
            "deadline": "60 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 380,
            "quote_end_line": 383
          },
          {
            "description": "Submit additional compliance reports within 10 days of written notice from FTC",
            "quoted_text": "with this order. Within ten (10) days of receipt of written notice from a representative of the Commission, it shall submit additional true and accurate written reports.",
            "deadline": "10 days",
            "verified": true,
            "confidence": 1.0,
            "quote_start_line": 383,
            "quote_end_line": 384
          }
        ]
      },
      {
        "provision_number": "XIV",
        "title": "Order Duration and Termination",
        "category": "duration",
        "summary": "The order will terminate on May 8, 2034, or 20 years from the most recent date the FTC files a complaint alleging violation, whichever is later.",
        "requirements": [
          {
            "description": "Order terminates on May 8, 2034, or 20 years from most recent FTC complaint filing, whichever is later",
            "quoted_text": "This order will terminate on May 8, 2034, or twenty (20) years from the most recent date that the United States or the Federal Trade Commission files a complaint (with or without an accompanying consent decree) in federal court alleging any violation of the order, whichever comes later; provided, however, that the filing of such a complaint will not affect the duration of: A. Any Part in this order that terminates in less than twenty (20) years; B. This order’s application to any respondent that is not named as a defendant in such complaint; and C. This order if such complaint is filed after the order has terminated pursuant to this Part. 10 Provided, further, that if such complaint is dismissed or a federal court rules that respondent did not violate any provision of the order, and the dismissal or ruling is either not appealed or upheld on appeal, then the order will terminate according to this Part as though the complaint had never been filed, except that the order will not terminate between the date such complaint is filed and the later of the deadline for appealing such dismissal or ruling and the date such dismissal or ruling is upheld on appeal.",
            "deadline": null,
            "verified": true,
            "confidence": 0.85,
            "quote_start_line": 386,
            "quote_end_line": 403
          }
        ]
      }
    ],
    "duration": {
      "duration_years": 20,
      "termination_text": "This order will terminate on May 8, 2034, or twenty (20) years from the most recent date that the United States or the Federal Trade Commission files a complaint (with or without an accompanying consent decree) in federal court alleging any violation of the order, whichever comes later; provided, however, that the filing of such a complaint will not affect the duration of: A. Any Part in this order that terminates in less than twenty (20) years; B. This order's application to any respondent that is not named as a defendant in such complaint; and C. This order if such complaint is filed after the order has terminated pursuant to this Part."
    }
  },
  "metadata": {
    "source_files": {
      "complaint": "05.14, Genelink Complaint.pdf",
      "order": "05.14, Genelink Order.pdf"
    },
    "extraction_stats": {
      "complaint_counts": 6,
      "complaint_representations": 5,
      "order_provisions": 14,
      "order_definitions": 14,
      "order_requirements": 42,
      "provisions_per_section": {
        "I": 1,
        "II": 1,
        "III": 2,
        "IV": 2,
        "V": 1,
        "VI": 9,
        "VII": 1,
        "VIII": 6,
        "IX": 9,
        "X": 2,
        "XI": 4,
        "XII": 1,
        "XIII": 2,
        "XIV": 1
      },
      "reextraction_stats": {
        "complaint_improved": 0,
        "order_improved": 0,
        "definitions_corrected": 0
      },
      "verification_details": {
        "complaint_verified": 5,
        "complaint_total": 5,
        "order_verified": 42,
        "order_total": 42
      }
    },
    "processing_time_seconds": 138.1
  }
}